ALPMF
ASTELLAS PHARMA INC
stock OTC

In the 2024 edition of the Drugs to Watch report by Clarivate (CLVT), significant medical advancements, such as the first RSV vaccines and groundbreaking gene therapy, are featured. The report identifies 13 recently launched or upcoming drugs with transformative potential, some expected to reach blockbuster status (generating over $1 billion in annual sales) within five years. Clarivate (CLVT) considered drugs launched early last year or undergoing Phase 2 and Phase 3 trials in the pre-registrational stage, excluding those launched before 2023.
Noteworthy technologies anticipated to prove their worth in 2024 include CRISPR-Cas9 gene editing and artificial intelligence/machine learning tools in drug discovery, clinical development, and commercial launch, as highlighted by Henry Levy, the head of Clarivate's Life Sciences & Healthcare segment.
Regeneron's (REGN) high-dose Eylea, a recently introduced therapy for eye diseases, takes the lead in the list. Clarivate (CLVT) emphasizes its efficacy and safety, projecting $1.77 billion in 2027 sales for Eylea HD from patients with wet age-related macular degeneration (AMD) in G7 countries alone.
Calliditas Therapeutics' (CALT) Budesonide, a delayed-release corticosteroid approved for adults with immunoglobulin A nephropathy, secures the second position. Datopotamab deruxtecan, a cancer therapy from AstraZeneca (AZN) and Daiichi Sankyo (OTCPK:DSKYF), holds the third spot, projected to be the second to launch for both HR-positive/HER2-negative and triple-negative breast cancer after Trodelvy from Gilead (GILD).
Roche (OTCQX:RHHBY) and Sobi's (OTCPK:BIOVF) Factor VIII replacement therapy, efanesoctocog alfa for hemophilia A, is fourth on the list, appealing for cases where novel treatments like gene therapies are unavailable. Verona Pharma's investigational therapy for COPD, ensifentrine, is also highlighted for its novelty.
Monoclonal antibodies Omvoh and zolbetuximab, developed by Eli Lilly (LLY) and Astellas Pharma's (OTCPK:ALPMF), respectively, complete the list. Clarivate (CLVT) notes Omvoh, approved for ulcerative colitis in October, remains a drug to watch in 2024 due to a delayed U.S. launch due to manufacturing concerns.
In its 2023 list, Clarivate (CLVT) highlighted 14 treatments, with 12 receiving regulatory approval. The challenges of drug launches are exemplified by Donanemab, Eli Lilly's (LLY) Alzheimer's therapy, and Roctavian, BioMarin's (BMRN) gene therapy for hemophilia A, which faced hurdles in regulatory approval and initial market reception, illustrating the complexities of drug launches, according to Clarivate's (CLVT) Levy.

In the 2024 edition of the Drugs to Watch report by Clarivate (CLVT), significant medical advancements, such as the first RSV vaccines and groundbreaking gene therapy, are featured. The report identifies 13 recently launched or upcoming drugs with transformative potential, some expected to reach blockbuster status (generating over $1 billion in annual sales) within five years. Clarivate (CLVT) considered drugs launched early last year or undergoing Phase 2 and Phase 3 trials in the pre-registrational stage, excluding those launched before 2023.
Noteworthy technologies anticipated to prove their worth in 2024 include CRISPR-Cas9 gene editing and artificial intelligence/machine learning tools in drug discovery, clinical development, and commercial launch, as highlighted by Henry Levy, the head of Clarivate's Life Sciences & Healthcare segment.
Regeneron's (REGN) high-dose Eylea, a recently introduced therapy for eye diseases, takes the lead in the list. Clarivate (CLVT) emphasizes its efficacy and safety, projecting $1.77 billion in 2027 sales for Eylea HD from patients with wet age-related macular degeneration (AMD) in G7 countries alone.
Calliditas Therapeutics' (CALT) Budesonide, a delayed-release corticosteroid approved for adults with immunoglobulin A nephropathy, secures the second position. Datopotamab deruxtecan, a cancer therapy from AstraZeneca (AZN) and Daiichi Sankyo (OTCPK:DSKYF), holds the third spot, projected to be the second to launch for both HR-positive/HER2-negative and triple-negative breast cancer after Trodelvy from Gilead (GILD).
Roche (OTCQX:RHHBY) and Sobi's (OTCPK:BIOVF) Factor VIII replacement therapy, efanesoctocog alfa for hemophilia A, is fourth on the list, appealing for cases where novel treatments like gene therapies are unavailable. Verona Pharma's investigational therapy for COPD, ensifentrine, is also highlighted for its novelty.
Monoclonal antibodies Omvoh and zolbetuximab, developed by Eli Lilly (LLY) and Astellas Pharma's (OTCPK:ALPMF), respectively, complete the list. Clarivate (CLVT) notes Omvoh, approved for ulcerative colitis in October, remains a drug to watch in 2024 due to a delayed U.S. launch due to manufacturing concerns.
In its 2023 list, Clarivate (CLVT) highlighted 14 treatments, with 12 receiving regulatory approval. The challenges of drug launches are exemplified by Donanemab, Eli Lilly's (LLY) Alzheimer's therapy, and Roctavian, BioMarin's (BMRN) gene therapy for hemophilia A, which faced hurdles in regulatory approval and initial market reception, illustrating the complexities of drug launches, according to Clarivate's (CLVT) Levy.